Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 71 results for "Acute Lymphoblastic Leukemia (ALL)".

Thumbnail for Does triple trisomy (+4, +10, +17) remain prognostically significant factor in pediatric high hyperdiploid acute lymphoblastic leukemia (HD-ALL)?

ALL - 428

Does triple trisomy (+4, +10, +17) remain prognostically significant factor in pediatric high hyperdiploid acute lymphoblastic leukemia (HD-ALL)?

Elza Lomaia

Poster Presenter: Elza Lomaia

Thumbnail for Deconvolution of Peripheral Blood Transcriptomes to Evaluate Immune Profiles Associated With Measurable Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Machine Learning-Driven Study

ALL - 486

Deconvolution of Peripheral Blood Transcriptomes to Evaluate Immune Profiles Associated With Measurable Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Machine Learning-Driven Study

Fatima Aslam

Poster Presenter: Fatima Aslam

Previous 1...3 4 5 6 7 8 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Disparities in B-Lymphoblastic Lymphoma: Insights From 1275 Patients in the National Cancer Database Treated at Academic and Community Cancer Centers

ALL - 507

Disparities in B-Lymphoblastic Lymphoma: Insights From 1275 Patients in the National Cancer Database Treated at Academic and Community Cancer Centers

Oscar Hinojosa

Poster Presenter: Oscar Hinojosa

Thumbnail for Identifying Drivers of Patient-Reported Treatment Burden to Inform Symptom Management in Newly Diagnosed Ph+ ALL: Results from the Phase 3 PhALLCON Study

ALL - 514

Identifying Drivers of Patient-Reported Treatment Burden to Inform Symptom Management in Newly Diagnosed Ph+ ALL: Results from the Phase 3 PhALLCON Study

Christopher Dieyi

Poster Presenter: Christopher Dieyi

Thumbnail for Systematic Literature Review and Network Meta-Analyses of Hypersensitivity in Patients Receiving Asparaginase Treatment

ALL - 576

Systematic Literature Review and Network Meta-Analyses of Hypersensitivity in Patients Receiving Asparaginase Treatment

Luke Maese

Poster Presenter: Luke Maese

$Thumbnail for Safety and Preliminary Efficacy of Olverembatinib (HQP1351) Combined With Lisaftoclax (APG-2575) in Children and Adolescents With Relapsed/Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: Results of a Phase 1b Study$

ALL - 584

Safety and Preliminary Efficacy of Olverembatinib (HQP1351) Combined With Lisaftoclax (APG-2575) in Children and Adolescents With Relapsed/Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: Results of a Phase 1b Study

Jeffrey Rubnitz

Poster Presenter: Jeffrey Rubnitz

Thumbnail for Safety and Feasibility of the CALGB 10403 Pediatric-Inspired Regimen in Adults With Acute Lymphoblastic Leukemia Older Than 40 Years

ALL - 588

Safety and Feasibility of the CALGB 10403 Pediatric-Inspired Regimen in Adults With Acute Lymphoblastic Leukemia Older Than 40 Years

Manuel Alejandro Cruz-Martinez

Poster Presenter: Manuel Alejandro Cruz-Martinez

Thumbnail for Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LBP) or Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

ALL - 589

Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LBP) or Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

Elias Jabbour

Poster Presenter: Elias Jabbour

Thumbnail for Updated Results of POLARIS-1 (Part 1), a Global Registrational Phase 3 Study: Olverembatinib Combined With Low-Intensity Chemotherapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

ALL - 597

Updated Results of POLARIS-1 (Part 1), a Global Registrational Phase 3 Study: Olverembatinib Combined With Low-Intensity Chemotherapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Suning Chen

Poster Presenter: Suning Chen

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors